ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 186 filers reported holding ASCENDIS PHARMA A/S in Q4 2023. The put-call ratio across all filers is 0.44 and the average weighting 0.7%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $3,390,680 | +64.5% | 24,862 | +82.3% | 3.49% | +68.1% |
Q1 2024 | $2,061,808 | -2.1% | 13,639 | -18.5% | 2.08% | -10.8% |
Q4 2023 | $2,106,640 | +35.1% | 16,726 | +0.4% | 2.33% | +15.6% |
Q3 2023 | $1,559,761 | +3.1% | 16,657 | -1.7% | 2.01% | +10.5% |
Q2 2023 | $1,512,520 | +32.4% | 16,947 | +59.1% | 1.82% | +15.1% |
Q1 2023 | $1,142,107 | -58.2% | 10,652 | -52.3% | 1.58% | -39.6% |
Q4 2022 | $2,729,239 | -9.3% | 22,347 | -23.3% | 2.62% | -9.5% |
Q3 2022 | $3,010,000 | +42.9% | 29,146 | +28.6% | 2.90% | +26.3% |
Q2 2022 | $2,106,000 | -52.1% | 22,659 | -39.6% | 2.29% | -25.0% |
Q1 2022 | $4,401,000 | -23.4% | 37,501 | -12.2% | 3.06% | +10.9% |
Q4 2021 | $5,746,000 | +55.1% | 42,712 | +83.8% | 2.76% | +67.8% |
Q3 2021 | $3,705,000 | +62.1% | 23,242 | +33.8% | 1.64% | +56.0% |
Q2 2021 | $2,285,000 | +5.7% | 17,370 | +3.6% | 1.05% | -17.5% |
Q1 2021 | $2,161,000 | +6.1% | 16,764 | +37.3% | 1.28% | -17.7% |
Q4 2020 | $2,037,000 | – | 12,212 | – | 1.55% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Vivo Capital, LLC | 2,003,147 | $225,574,000 | 20.44% |
RA Capital Management | 4,914,955 | $553,473,000 | 17.48% |
Sofinnova Investments, Inc. | 1,109,874 | $124,983,000 | 11.56% |
Eversept Partners, LP | 275,494 | $31,023,379 | 7.71% |
Avoro Capital Advisors LLC | 1,787,000 | $201,234,000 | 6.79% |
Orbimed Advisors | 3,287,400 | $370,194,000 | 6.22% |
Eventide Asset Management | 1,698,648 | $191,285,000 | 6.19% |
Logos Global Management LP | 120,000 | $13,513,000 | 5.14% |
Ghost Tree Capital, LLC | 150,000 | $16,892,000 | 4.48% |
Spyglass Capital Management LLC | 351,388 | $39,570,000 | 4.47% |